259 related articles for article (PubMed ID: 17072337)
1. Regulation of survivin expression by IGF-1/mTOR signaling.
Vaira V; Lee CW; Goel HL; Bosari S; Languino LR; Altieri DC
Oncogene; 2007 Apr; 26(19):2678-84. PubMed ID: 17072337
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
3. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation.
Roca H; Varsos Z; Pienta KJ
J Biol Chem; 2008 Sep; 283(36):25057-73. PubMed ID: 18611860
[TBL] [Abstract][Full Text] [Related]
4. Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells.
Song K; Shankar E; Yang J; Bane KL; Wahdan-Alaswad R; Danielpour D
PLoS One; 2013; 8(5):e61896. PubMed ID: 23658701
[TBL] [Abstract][Full Text] [Related]
5. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter.
Chun JY; Hu Y; Pinder E; Wu J; Li F; Gao AC
Mol Cancer Ther; 2007 Sep; 6(9):2572-80. PubMed ID: 17876054
[TBL] [Abstract][Full Text] [Related]
6. Regulation of survivin by PI3K/Akt/p70S6K1 pathway.
Zhao P; Meng Q; Liu LZ; You YP; Liu N; Jiang BH
Biochem Biophys Res Commun; 2010 Apr; 395(2):219-24. PubMed ID: 20361940
[TBL] [Abstract][Full Text] [Related]
7. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
[TBL] [Abstract][Full Text] [Related]
8. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling.
Zhang D; Brodt P
Oncogene; 2003 Feb; 22(7):974-82. PubMed ID: 12592384
[TBL] [Abstract][Full Text] [Related]
9. [Biological implications of the inhibition of survivin by RNA interference in human androgen-independent prostate carcinoma with highly metastatic potential].
Zhu X; Ning JY; You JF; Wang JL; Cui XL; Fang WG; Zheng J
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):549-54. PubMed ID: 17134550
[TBL] [Abstract][Full Text] [Related]
10. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells.
Paduano F; Villa R; Pennati M; Folini M; Binda M; Daidone MG; Zaffaroni N
Mol Cancer Ther; 2006 Jan; 5(1):179-86. PubMed ID: 16432177
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
12. IGF-IR-dependent expression of Survivin is required for T-antigen-mediated protection from apoptosis and proliferation of neural progenitors.
Gualco E; Urbanska K; Perez-Liz G; Sweet T; Peruzzi F; Reiss K; Del Valle L
Cell Death Differ; 2010 Mar; 17(3):439-51. PubMed ID: 19834489
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
[TBL] [Abstract][Full Text] [Related]
14. CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.
Roca H; Varsos ZS; Pienta KJ
Neoplasia; 2009 Dec; 11(12):1309-17. PubMed ID: 20019839
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
16. [Down-regulation of mTOR activity and survivin expression during tamoxifen-induced apoptosis in hepatoblastoma cells].
Guo RH; Wang TS; Chen XF; Huang ZH; Shu YQ
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):903-6. PubMed ID: 21223797
[TBL] [Abstract][Full Text] [Related]
17. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
18. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.
Pennati M; Binda M; Colella G; Zoppe' M; Folini M; Vignati S; Valentini A; Citti L; De Cesare M; Pratesi G; Giacca M; Daidone MG; Zaffaroni N
Oncogene; 2004 Jan; 23(2):386-94. PubMed ID: 14724567
[TBL] [Abstract][Full Text] [Related]
19. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
Ai Z; Yin L; Zhou X; Zhu Y; Zhu D; Yu Y; Feng Y
Cancer; 2006 Aug; 107(4):746-56. PubMed ID: 16826583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
